Hybrid-based multi-target ligands for the treatment of Alzheimer's disease

Current Topics in Medicinal Chemistry

Volumn 11, Issue 22, 2011, Pages 2716-2730

  Rampa, Angela ^a   Belluti, Federica ^a   Gobbi, Silvia ^a   Bisi, Alessandra ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Amyloid beta peptide; Drug design; Hybrid compounds; Multitarget

Indexed keywords

AMYLOID BETA PROTEIN; AP 2238; BENZOFURAN DERIVATIVE; BERBERINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HUPERZINE A; HUPERZINE B; MEMANTINE; MEPTAZINOL; NIMODIPINE; RIVASTIGMINE; SKF 64346; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BINDING SITE; CLINICAL FEATURE; DIARRHEA; DISEASE COURSE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYBRIDIZATION; LIVER TOXICITY; NEUROPROTECTION; NEUROTRANSMISSION; PROTEIN AGGREGATION; REVIEW; SENILE PLAQUE; TREATMENT PLANNING; UPREGULATION;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; HUMANS; LIGANDS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 82055186741     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798184409     Document Type: Review

References (122)

1. Alzheimer, A. Übereine eigenartige Erkaung der Hirnrinde Allg. Z. Psychiatr., 1907, 146-148. s
2. Selkoe, D.J. Developing preventive therapies for chronic diseases: Lessons learned from Alzheimer's disease. Nutr. Rev., 2007, 65 (Suppl. 64), S239-S243.
3. Greene, J.D.; Baddeley, A.D.; Hodges, J.R. Analysis of the episodic memory deficit in early Alzheimer's disease: Evidence from the doors and people test. Neuropsychologia, 1996, 537-551.
4. Price, B.H.; Gurvit, H.; Weintraub, S.; Geula, C.; Leimkuhler, E.; Mesulam, M. Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer's disease. Arch. Neurol., 1993, 931-937.
5. Esteban-Santillán, C.; Praditsuwan, R.; Ueda, H.; Geldmacher, D.S. Clock drawing test in very mild Alzheimer's disease. J. Am. Geriatr. Soc., 1998, 1266-1269.
6. Coleman, P.; Federoff, H.; Kurlan, R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology, 2004, 1155-1162.
7. Desai, A.K.; Grossberg, G.T. Diagnosis and treatment of Alzheimer's disease. Neurology, 2005, 64 S34-S39.
8. Terry, A.V.; Buccafusco, J.J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther., 2003, 306, 821-827.
9. Cummings J.L. Alzheimer's disease. N. Engl. J. Med., 2004, 351, 56-67.
10. Darvesh, S.; Hopkins, D.A.; Geula, C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci., 2003, 4, 131-138.
11. Greig, N.H.; Utsuki, T.; Ingram, D.K.; Wang, Y.; Pepeu, G.; Scali, C.; Yu, Q.S.; Mamczarz, J.; Holloway, H.W.; Giordano, T.; Chen, D.; Furukawa, K.; Sambamurti, K.; Brossi, A.; Lahir, D.K. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci., 2005, 102, 17213-17218.
12. Giacobini, E. Cholinergic function and Alzheimer's disease. Int. J. Geriatr. Psychiatry, 2003, 18, S1-S5.
13. Bartorelli, L.; Giraldi, C.; Saccardo, M.; Cammarata, S.; Bottini, G.; Fasanaro, A.M.; Trequattrini, A. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr. Med. Res. Opin., 2005, 21, 1809-18.
14. Farlow, M.; Anand, R.; Messina, J. Jr.; Hartman, R.; Veach, J. A 52-week study of the efficacy of rivastigmin in patients with mild to moderately severe Alzeimer's disease. Eur. Neurol., 2000, 44, 236-241.
15. Buee, L.; Bussiere, T.; Buee-Scherrer, V.; Delacourte, A.; Hof, P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev., 2000, 33, 95-130.
16. Palmert, M.R.; Podlisny, M.B.; Witker, D.S.; Oltersdorf, T.; Younkin, L.H.; Selkoe, D.J.; Younkin, S.G. The b-amyloid protein precursor of Alzheimer's disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc. Natl, Acad. Sci. USA, 1989, 86, 6338-6342.
17. Näslund, J.; Schierhorn, A.; Hellman, U.; Lannfelt, L.; Roses, A.D.; Tjernberg, L.O.; Silberring, J.; Gandy, S.E.; Winblad, B.; Greengard, P. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl, Acad. Sci. USA, 1994, 91, 8378-8382.
18. Bartolini, M.; Bertucci, C.; Bolognesi, M.L.; Cavalli, A.; Melchiorre, C.; Andrisano, V. Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: Elucidation of inhibitors' mechanism of action. Chembiochem, 2007, 8, 2152-2161.
19. Finder, V.H.; Glockshuber, R. Amyloid-b aggregation. Neurodegenerative Dis., 2007, 4, 13-27.
20. Estrada, L.D.; Soto, C. Disrupting b-Amyloid aggregation for Alzheimer's disease treatment. Curr. Topics Med. Chem., 2007, 7, 115-126.
21. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 2002, 297, 353-356.
22. Praticò, D. Oxidative stress hypothesis in Alzheimer's disease: A reappraisal. Trends Pharmacol. Sci., 2008, 29, 609-615.
23. Greig, N.H.; Giacobini, E.; Lahiri, D.K. Advances in Alzheimer therapy and development of innovative new strategies. Curr. Alzheimer Res., 2007, 4, 336-339.
24. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543.
25. Morphy, R.; Rankovic, Z. Fragment, network biology and designing multiple ligands. Drug Discov. Today, 2007, 12, 156-160.
26. Youdim, M.B.H.; Buccafusco, J.J. Multi-functional drugs for various CNS target in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci., 2005, 26, 27-35.
27. Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-Directed Ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51, 347-372.
28. Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Melchiorre, C. From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): A step forward in the treatment of Alzheimer's disease. Mini Rev. Med. Chem., 2008, 8, 960-967.
29. Bolognesi, M.L.; Rosini, M.; Andrisano, V.; Bartolini, M.; Minarini, A.; Tumiatti, V.; Melchiorre, C. MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond. Curr. Pharm. Des., 2009, 15, 601-613.
30. Cavalli, A.; Bolognesi, M.L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew. Chem., Int. Ed., 2007, 46, 3689-3692.
31. Bolognesi, M.L.; Cavalli, A.; Melchiorre, C. Memoquin: A multitarget-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics, 2009, 6, 152-162.
32. Pang, Y.P.; Quiram, P.; Jelacic, T.; Hong, F.; Brimijoin, S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem., 1996, 271, 23646-23649.
33. Muñoz-Torrero, D. Acetylcholinesterase inhibitors as diseasemodifying therapies for Alzheimer's disease. Curr. Med. Chem., 2008, 15, 2433-2455.
34. Inestrosa, N.C.; Álvarez, A.; Pérez, C.A.; Moreno, R.D.; Vicente, M.; Linker, C.; Casanueva, O.I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-betapeptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron, 1996, 16, 881-891.
35. De Ferrari, G.V.; Canales, M.A.; Shin, I.; Weiner, L.M.; Silman, I.; Inestrosa, N.C.A Structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation Biochemistry, 2001, 40, 10447-10457.
36. Cavalli, A.; Bottegoni, G.; Raco, C.; De Vivo, M.; Recanatini, M. A computational study of the binding of propidium to the peripheral anionic site of human acetylcholinesterase. J. Med. Chem., 2004, 47, 3991-3999
37. Bourne, Y.; Taylor, P.; Radić, Z.; Marchot, P. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site. EMBO J., 2003, 22, 1-12.
38. Bolognesi, M.L.; Andrisano, V.; Bartolini, M.; Banzi, R.; Melchiorre, C. Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-Induced amyloid-b aggregation. J. Med. Chem., 2005, 48, 24-27.
39. ®) derivaties. Bioorg. Med. Chem. Lett., 1992, 2, 861-864.
40. Recanatini, M.; Cavalli, A, Belluti, F.; Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Valenti, P.; Andrisano, V.; Bartolini, M.; Cavrini, V. SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: Synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of Tacrine analogues. J. Med. Chem., 2000, 43, 2007-2018.
41. Muñoz-Ruiz, P.; Rubio, L.; Garcia-Palomero, E.; Dorronsoro, I.; del Monte-Millán, M.; Valenzuela, R.; Usán, P.; de Austria, C.; Bartolini, M.; Andrisano, V.; Bidon-Chanal, A.; Orozco, M.; Luque, F.J.; Medina, M.; Martínez, A. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: New disease-modifying agents for Alzheimer's disease. J. Med. Chem., 2005, 48, 7223-7233.
42. García-Palomero, E.; Muñoz, P.; Usán, P.; García, P.; Delgado, E.; De Austria, C.; Valenzuela, R.; Rubio, L.; Medina, M.; Martínez, A. Potent b-amyloid modulators. Neurodegener. Dis., 2008, 5, 153-156.
43. Doraiswamy, P.M.; Finefrock, A.E. Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol., 2004, 431-434.
44. Gaeta, A.; Hider, R.C. The crucial role of metal ions in neurodegeneration: The basis for a promising therapeutic strategy. Br. J. Pharmacol., 2005, 146, 1041-1059.
45. Gaggelli, E.; Kozlowski, H.; Valensin, D.; Valensin, G. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem. Rev., 2006, 106, 1995-2044.
46. Bolognesi, M.L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; Andrisano, V.; Recanatini, M.; Melchiorre, C. Multi-targetdirected drug design strategy: From a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J. Med. Chem., 2007, 50, 6446-6449.
47. Alonso, D.; Dorronsoro, I.; Rubio, L.; Muñoz, P.; García-Palomero, E.; Del Monte, M.; Bidon-Chanal, A.; Orozco, M.; Luque, F.J.; Castro, A.; Medina, M.; Martínez, A. Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorg. Med. Chem., 2005, 13, 6588-6597.
48. Kryger, G.; Silman, I.; Sussman, J.L. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure, 1999, 7, 297-307.
49. Harel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P.; Silman, I.; Sussman, J.L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. USA, 1993, 90, 9031-9035.
50. Shao, D.; Zou, C.; Luo, C.; Tang, X.; Li, Y. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett., 2004, 14, 4639-4642.
51. Camps, P.; Formosa, X.; Galdeano, C.; Gómez, T.; Muñoz-Torrero, D.; Scarpellini, M.; Viayna, E.; Badía, A.; Clos, M.V.; Camins, A.; Pallàs, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Estelrich, J.; Lizondo, M.; Bidon-Chanal, A.; Luque, F.J. Novel donepezil-based inhibitors of acetyl-and butyrylcholinesterase and acetylcholinesterase-induced b-amyloid aggregation. J. Med. Chem., 2008, 51, 3588-3598.
52. Camps, P.; El Achab, R.; Görbig, D.M.; Morral, J.; Muñoz-Torrero, D.; Badía, A.; Baños, J.E.; Vivas, N.M.; Barril, X.; Orozco, M.; Luque, F.J. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. J. Med. Chem., 1999, 42, 3227-3242.
53. Camps, P.; Formosa, X.; Muñoz-Torrero, D.; Petrignet, J.; Badía, A.; Clos, M.V. Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: Subnanomolar dual binding site acetylcholinesterase inhibitors. J. Med. Chem., 2005, 48, 1701-1704.
54. Ronco, C.; Sorin, G.; Nachon, F.; Foucault, R.; Jean, L.; Romieu, A.; Renard, P.-Y. Synthesis and structure-activity relationship of huprine derivatives as human acetylcholinesterase inhibitors. Bioorg. Med. Chem., 2009, 17, 4523-4536.
55. Camps, P.; Formosa, X.; Galdeano, C.; Muñoz-Torrero, D.; Ramírez, L.; Gómez, E.; Isambert, N.; Lavilla, R.; Badía, A.; Clos, M.V.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M.P.; Rodríguez-Franco, M.I.; Huertas, O.; Dafni, T.; Luque, F.J. Pyrano [3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase and β-amyloid-directed anti-Alzheimer compounds. J. Med. Chem., 2009, 52, 5365-5379.
56. Zhang, L.; Xing, G.Q.; Barker, J.L.; Chang, Y.; Maric, D.; Ma, W.; Li, B.S.; Rubinow, D.R. a-Lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. Neurosci. Lett., 2001, 312, 125-128.
57. Hager, K.; Marahrens, A.; Kenklies, M.; Riederer, P.; Munch, G. a -Lipoic acid as a new treatment option for Azheimer type dementia. Arch. Gerontol. Geriatr., 2001, 32, 275-282.
58. Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M.L.; Hrelia, P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem., 2005, 48, 360-363.
59. Decker, M.; Krauth, F.; Lehmann, J. Novel tricyclic quinazolinimines and related tetracyclic nitrogen bridgehead compounds as cholinesterase inhibitors with selectivity towards butyrylcholinesterase. Bioorg. Med. Chem., 2006, 14, 1966-1977.
60. Decker, M. Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase. J. Med. Chem., 2006, 49, 5411-5413.
61. Decker, M.; Krausb, B.; Heilmann, J. Design, synthesis and pharmacological evaluation of hybrid molecules out of quinazolinimines and lipoic acid lead to highly potent and selective butyrylcholinesterase inhibitors with antioxidant properties. Bioorg. Med. Chem., 2008, 16, 4252-4261.
62. Heilmann, J.; Çalis, I.; Kirmizbekmez, H.; Schühly, W.; Harput, S.; Sticher, O. Radical scavenger activity of phenylethanoid glycosides in FMLP stimulated human polymorphonuclear leukocytes: structure-activity relationships. Planta Med., 2000, 66, 746-748.
63. Fang, L.; Kraus, B.; Lehmann, J.; Heilmann, J.; Zhangb, Y.; Decker, M. Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg. Med. Chem. Lett., 2008, 18, 2905-2909.
64. Reiter, R.J. Oxidative damage in the central nervous system: Protection by melatonin. Prog. Neurobiol., 1998, 56, 359-384.
65. Jang, M.H.; Jung, S.B.; Lee, M.H.; Kim, C.J.; Oh, Y.T.; Kang, I.; Kim, J.; Kim, E.H. Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells. Neurosci. Lett., 2005, 380, 26-31.
66. Baydas G.; Ozer M.; Yasar A.; Tuzcu M.; Koz S.T. Melatonin improves learning and memory performances impaired by hyperhomocysteinemia in rats. Brain Res., 2005, 1046, 187-194.
67. Rodríguez-Franco, M.I.; Fernández-Bachiller, M.I.; Pérez, C.; Hernández-Ledesma, B.; Bartolomé, B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer's disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem. 2006, 49, 459-462.
68. Fernández-Bachiller, M.I.; Pérez, C.; Campillo, N.E.; Páez, J.A.; González-Muñoz, G.C.; Usán, P.; García-Palomero, E.; López, M.G.; Villarroya, M.; García, A.G.; Martínez, A.; Rodríguez-Franco, M.I. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's sisease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem, 2009, 4, 828-841.
69. Spuch, C.; Antequera, D.; Fernández-Bachiller, M.I.; Rodríguez-Franco, M.I.; Carro, E.A. New tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease. Neurotox. Res., 2010, 17, 421-431.
70. Melnikova, I. Therapies for Alzheimer's disease. Nat. Rev. Drug Discov., 2007, 6, 341-342.
71. Lipton, S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat. Rev. Drug Discov., 2006, 5, 160-170.
72. Dantoine, T.; Auriacombe, S.; Sarazin, M.; Becker, H.; Pere, J.J.; Bourdeix, I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int. J. Clin. Pract., 2006, 60, 110-118.
73. Riepe, M.W.; Adler, G.; Ibach, B.; Weinkauf, B.; Gunay, I.; Tracik, F. Adding memantine to rivastigmine therapy in patients with mildto-moderate Alzheimer's disease: Results of a 12-week, openlabel pilot study. Primary Care Companion J. Clin. Psychiatr., 2006, 8, 258-263.
74. Creeley, C.E.; Wozniak, D.F.; Nardi, A.; Farber, N.B.; Olney, J.W. Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain. Neurobiol. Aging, 2008, 29, 153-167.
75. Woodruff-Pak, D.S.; Tobia, M.J.; Jiao, X.; Beck, K.D.; Servatius, R.J. Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil. Neuropsychopharmacology, 2007, 32, 1284-1294.
76. Walter, M.F.; Mason, R.P. Neuroprotective activities of carvedilol and a hydroxylated derivative: role of membrane biophysical interactions. Biochem. Pharmacol., 1998, 56, 1645-1656.
77. Howlett, D.R.; George, A.R.; Owen, D.E.; Ward, R.V.; Markwell, R.E. Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation. Biochem. J., 1999, 343 (Part 2), 419-423.
78. Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; Pascu, N.; McClymont, D.W.; Tarozzi, A.; Bolognesi, M.L.; Minarini, A.; Tumiatti, V.; Andrisano, V.; Mellor, I.R.; Melchiorre, C. Inhibition of acetylcholinesterase, _-amyloid aggregation, and NMDA receptors in Alzheimer's disease: A promising direction for the multi-target-directed ligands. J. Med. Chem., 2008, 51, 4381-4384.
79. Kruman, I.; Guo, Q.; Mattson, M.P. Calcium and reactive oxygen species mediate staurosporine-induced mitochondrial dysfunction and apoptosis in PC12 cells. J. Neurosci. Res., 1998, 51, 293-308.
80. Mattson, M.P.; Cheng, B.; Davis, D.; Bryant, K.; Lieberburg, I.; Rydel, R.E. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci., 1992, 12, 376-389.
81. Cano-Abad, M.F.; Villarroya, M.; García, A.G.; Gabilán, N.H.; López, M.G. Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death. J. Biol. Chem., 2001, 276, 39695-39704.
82. Sobrado, M.; López, M.G.; Carceller, F.; García, A.G.; Roda, J.M. Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis, and increase bcl-2 expression after focal cerebral ischemia. Neuroscience, 2003, 118, 107-113.
83. Marco-Contelles, J.; León, R.; De Los Ríos, C.; Guglietta, A.; Terencio, J.; López, M.G.; García, A.G.; Villarroya, M. Novel multipotent tacrine-dihydropyridine hybrids with improbe acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem., 2006, 49, 7607-7610.
84. Marco-Contelles, J.; León, R.; De Los Ríos, C.; Samadi, A.; Bartolini, M.; Andrisano, V.; Huertas, O.; Barril, X.; Luque, F.J.; Rodríguez-Franco, M.I.; López, B.; López, M.G.; García, A.G.; do Carmo Carreiras, M.; Villarroya, M. Tacripyrines, the first tacrinedihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. J. Med. Chem., 2009, 52, 2724-2732.
85. Marco-Contelles, J.; León, R.; De Los Ríos, C.; García, A.G.; López, M.G.; Villarroya, M. New multipotent tetracyclic tacrines with neuroprotective activity. Bioorg. Med. Chem., 2006, 14, 8176-8185.
86. León, R.; De Los Ríos, C.; Marco-Contelles, J.; Huertas, O.; Barril, X.; Luque, F.J.; López, M.G.; García, A.G.; Villarroya, M. New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties. Bioorg. Med. Chem., 2008, 16, 7759-7769.
87. Duncan, A.J.; Heales, S.J.R. Nitric oxide and neurological disorders. Mol. Aspects Med., 2005, 26, 67-96.
88. Megson, I.L.; Webb, D.J. Nitric oxide donor drugs: Current status and future trends. Expert Opin. Invest. Drugs, 2002, 11, 587-601.
89. Thatcher, G.R.J.; Bennett, B.M.; Reynolds, J.N. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res., 2005, 2, 171-182.
90. Fang, L.; Appenroth, D.; Decker, M.; Kiehntopf, M.; Roegler, C.; Deufel, T.; Fleck, C.; Peng, S.Y.Z.; Lehmann, J. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J. Med. Chem., 2008, 51, 713-716.
91. Zhu, X.D.; Tang, X.C. Improvement of impaired memory in mice by huperzine A and huperzine B. Acta Pharmacol. Sin., 1988, 9, 492-497.
92. Bai, D.L.; Tang, X.C.; He, X.C. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr. Med. Chem., 2000, 7, 355-374.
93. Wang, R.; Yan, H.; Tang, X.C. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol. Sin., 2006, 27, 1-26.
94. Liu, J.; Zhang, H.Y.; Wang, L.M.; Tang, X.C. Inhibitory effects of huperzine B on cholinesterase activity in mice. Acta Pharmacol. Sin., 1999, 20, 141-145.
95. Feng, S.; Wang, Z.; He, X.C.; Zheng, S.; Xia, Y.; Jiang, H.; Tang, X.; Bai, D. Bis-huperzine B: Highly potent and selective acetylcholinesterase inhibitors. J. Med. Chem., 2005, 48, 655-657.
96. He, X.C.; Feng, S.; Wang, Z. F.; Shi, Y.; Zheng, S.; Xia, Y.; Jiang, H.; Tang, X. C.; Bai, D. Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis-and bifunctional huperzine B. Bioorg. Med. Chem., 2007, 15, 1394-1408.
97. Dvir, H.; Jiang, H.L.; Wong, D.M.; Harel, M.; Chetrit, M.; He, X.C.; Jin, G.Y.; Yu, G.L.; Tang, X.C.; Silman, I.; Bai, D.L.; Sussman, J.L. X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: Structural evidence for an active site rearrangement. Biochemistry, 2002, 41, 10810-10818.
98. Shi, Y-F.; Zhang, H.; Wang, W.; Fu, Y.; Xia, Y.; Tang, X.; Bai, D.; He, X.C. Novel 16-substituted bifunctional derivatives of huperzine B: Multifunctional cholinesterase inhibitors. Acta Pharmacol. Sin., 2009, 30, 1195-1203.
99. Cho, K.M.; Yoo, I.D.; Kim, W.G. 8-Hydroxydihydrochelerythrine and 8-hydroxydihydrosanguinarine with a potent acetylcholinesterase inhibitory activity from Chelidonium majus L. Biol. Pharm. Bull., 2006, 29, 2317-2320.
100. Li, Y.H.; Peng, Y.; Kong, W.J.; Wang, Y.X.; Hu, C.Q.; Zuo, Z.Y.; Wang, Y.M.; Gao, H.; Gao, L.M.; Feng, Y.C.; Du, N.N.; Liu, Y.; Song, D.Q.; Jiang, J.D. Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: Synthesis, structure-activity relationships, and cholesterol-lowering efficacy. J. Med. Chem., 2009, 52, 492-501.
101. Huang, L.; Shi, A.; He, F.; Li, X. Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg. Med. Chem., 2010, 18, 1244-1251.
102. Li, W.; Hao, J.; Tang, Y.; Chen, Y.; Qiu, Z. Comparative studies of X-ray determined meptazinol enantiomers with analgesic pharmacophore. Acta. Pharmacol. Sin., 2005, 26, 334-338.
103. Ennis, C.; Harounì, F.; Lattimer, N. Can the effects of meptazinol on the guinea-pig isolated ileum be explained by inhibition of acetylcholinesterase? J. Pharm. Pharmacol., 1986, 38, 24-27.
104. Xie, Q.; Tang, Y.; Li, W.; Wang, X.; Qiu, Z. Investigation of the binding mode of (-)-meptazinol and bis-meptazinol derivatives on acetylcholinesterase using a molecular docking method. J. Mol. Model., 2006, 12, 390-397.
105. Xie, Q.; Wang, H.; Xia, Z.; Lu, M.; Zhang, W.; Wang, X.; Fu, W.; Tang, Y.; Sheng, W.; Li, W.; Zhou, W.; Zhu, X.; Qiu, Z.; Chen, H. Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid- aggregation. J. Med. Chem., 2008, 51, 2027-2036.
106. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.; Andrisano, V.; Valenti, P.; Recanatini, M. 3-(4-{[Benzyl(methyl)amino]methyl}phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation: A dual function lead for Alzheimer's disease therapy. J. Med. Chem., 2003, 46, 2279-2281.
107. Piazzi, L.; Cavalli, A.; Belluti, F.; Bisi, A.; Gobbi, S.; Rizzo, S.; Bartolini, M.; Andrisano, V.; Recanatini, M.; Rampa, A. Extensive SAR and computational studies of 3-(4-{[benzyl(methyl)amino]methyl}phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) derivatives. J. Med. Chem., 2007, 50, 4250-4254.
108. Drug Data Report, 2002, 24, 119, 309, 597, 885.
109. Guo, T.; Hobbs, D.W. Development of BACE1 inhibitors for Alzheimer's disease. Curr. Med. Chem., 2006, 13, 1811-1829.
110. Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; Recanatini, M.; Andrisano, V.; Rampa, A. Multi-targetdirected coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg. Med. Chem. Lett., 2008, 18, 423-426.
111. Rizzo, S.; Bartolini, M.; Ceccarini, L.; Piazzi, L.; Gobbi, S.; Cavalli, A.; Recanatini, M.; Andrisano, V.; Rampa, A. Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238. Bioorg. Med. Chem., 2010, 18, 1749-1760.
112. Howlett, D.R.; Perry, A.E.; Godfrey, F.; Swatton, J.E.; Jennings, K.H.; Spitzfaden, C.; Wadsworth, H.; Wood, S.J.; Markwell, R.E. Inhibition of fibril formation in _-amyloid peptide by a novel series of benzofurans. Biochem. J., 1999, 340, 283-289.
113. Rampa, A.; Piazzi, L.; Belluti, F.; Gobbi, S.; Bisi, A.; Bartolini, M.; Andrisano, V.; Cavrini, V.; Cavalli, A.; Recanatini, M.; Valenti, P. Acetylcholinesterase Inhibitors: SAR and kinetic studies on _-[Nmethyl-N-(3-alkylcarbamoyloxyphenyl)-methyl]-aminoalkoxyaryl derivatives. J. Med. Chem., 2001, 44, 3810-3820.
114. Belluti, F.; Rampa, A.; Piazzi, L.; Bisi, A.; Gobbi, S.; Bartolini, M.; Andrisano, V.; Cavalli, A.; Recanatini, M.; Valenti, P. Cholinesterase inhibitors: Xanthostigmine derivatives blocking the acetylcholinesterase-induced β-amyloid aggregation. J. Med. Chem., 2005, 48, 4444-4456.
115. Piazzi, L.; Belluti, F.; Bisi, A.; Gobbi, S.; Rizzo, S.; Bartolini, M.; Andrisano, V.; Recanatini, M.; Rampa, A. Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[_-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg. Med. Chem., 2007, 15, 575-585.
116. Rizzo, S.; Cavalli, A.; Ceccarini, L.; Bartolini, M.; Belluti, F.; Bisi, A.; Andrisano, V.; Recanatini, M.; Rampa, A. Structure-activity relationships and binding mode in the human acetylcholinesterase active site of pseudo-irreversible inhibitors related to xanthostigmine. ChemMedChem, 2009, 4, 670-679.
117. Klegeris, A.; Walker, D.G.; McGeer, P.L. Activation of macrophages by Alzheimer beta amyloid peptide. Biochem. Biophys. Res. Commun., 1994, 199, 984-991.
118. Pike, C.J.; Walencewicz-Wasserman, A.J.; Kosmoski, J.; Cribbs, D.H.; Glabe, C.G.; Cotman, C.W. Structure-activity analyses of beta-amyloid peptides: Contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem., 1995, 64, 253-265.
119. Rizzo, S.; Rivière, C.; Piazzi, L.; Bisi, A.; Gobbi, S.; Bartolini, M.; Andrisano, V.; Morroni, F.; Tarozzi, A.; Monti, J-P.; Rampa, A. Benzofuran-based hybrid compounds for the inhibition of cholinesterase activity, A aggregation and A neurotoxicity. J. Med. Chem., 2008, 51, 2883-2886.
120. Kimura, M.; Akasofu, S.; Ogura, H.; Sawada, K. Protective effect of donepezil against Abeta (1-40) neurotoxicity in rat septal neurons. Brain Res., 2005, 1047, 72-84.
121. Eskander, M.F.; Nagykery, N.G.; Leung, E.Y.; Khelghati, B.; Geula, C. Rivastigmine is a potent inhibitor of acetyl-and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Res., 2005, 1060, 144-152.
122. Takada-Takatori, Y.; Kume, T.; Sugimoto, M.; Katsuki, H.; Sugimoto, H.; Akaike, A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology, 2006, 51, 474-486.